LALiliane Silvano Araújo

Liliane Silvano Araújo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liliane Silvano Araújo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tissue Expression of NLRP3, IL‐1β, and IL‐18 in Glomerular and Interstitial Inflammation Associated With Diabetic Nephropathy

    by Bruna de Freitas Oliveira, Liliane Silvano Araújo, Crislaine Aparecida da Silva, Laura Penna Rocha, Raíssa Bernardes da Silva, Marlene Antônia dos Reis, Rafael Obata Trevisan, Bruna Cunha Zaidan, Juliana Reis Machado

    Activation of the NLRP3 inflammasome and its downstream cytokines IL‐1β and IL‐18 has been increasingly associated with the inflammatory mechanisms underlying diabetic nephropathy (DN), the leading cause of chronic kidney disease and end‐stage renal disease worldwide. This study investigated the expression of these inflammatory mediators in renal tissue from patients with DN. Eighty renal biopsies from adult patients (≥18 years) with a histopathological diagnosis of DN and 22 control samples obtained from autopsies were analyzed. NLRP3, IL‐1β, and IL‐18 expression was assessed by immunohistochemistry, and semi‐quantitative analysis was performed to determine the proportion of immunostained cells in the glomerular and interstitial compartments. A significant increase in immunostaining for all three mediators was observed in mesangial cells, podocytes, endothelial cells, and the interstitium of DN samples compared with controls ( p < 0.05). Positive and significant correlations were found between NLRP3 and IL‐1β in endothelial cells ( p < 0.0001; rS = 0.4720) and in the interstitium ( p = 0.0230; rS = 0.2540), as well as between NLRP3 and IL‐18 in podocytes ( p = 0.0055; rS = 0.3074). Moreover, interstitial expression of NLRP3 and IL‐1β correlated positively with serum creatinine levels ( p = 0.0015; rS = 0.3708; and p = 0.0029; rS = 0.3480, respectively), suggesting an association between inflammasome‐mediated inflammation and renal dysfunction. Collectively, these findings indicate that the NLRP3/IL‐1β/IL‐18 axis plays a central role in glomerular and interstitial injury in DN, supporting its potential as a prognostic biomarker and a promising therapeutic target for disease modulation.


  • Open Access

    Evaluation of the Diagnostic Potential of uPAR as a Biomarker in Renal Biopsies of Patients with FSGS

    by Crislaine Aparecida da Silva, Liliane Silvano Araújo, Maria Luíza Gonçalves dos Reis Monteiro, Lívia Helena de Morais Pereira, Marcos Vinícius da Silva, Lúcio Roberto Cançado Castellano, Rosana Rosa Miranda Corrêa, Marlene Antônia dos Reis, Juliana Reis Machado

    Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are primary glomerulopathies leading to proteinuria, known as podocytopathies, which share syndromic and morphological similarities. Morphological similarity occurs in cases of FSGS in which the sclerotic lesion was not sampled in renal biopsy, due to the focal nature of the disease. Differentiating these entities is very important, especially in cases of suspected FSGS but with sclerotic lesion not sampled, as they are diseases that apparently have different pathogenic mechanisms and prognosis. The difference in uPAR expression in situ among these two entities may be related to a distinct molecular mechanism involved in pathogenesis. Thus, finding biomarkers involved in the pathogenesis and that can also help in differential diagnosis is very relevant. The aim of this work was to evaluate the potential of urokinase-type plasminogen activator receptor (uPAR) as a biomarker in renal biopsies of patients with podocytopathies (n=38). Immunohistochemistry showed that FSGS (n=22) had increased uPAR expression in podocytes compared with both the MCD group (n=16; p=0.0368) and control group (n=21; p=0.0076). ROC curve (p=0.008) showed that this biomarker has 80.95% of specificity in biopsies of patients with FSGS. Therefore, uPAR presented a high specificity in cases of podocytopathies associated with sclerosis and it can be considered a potential biomarker for FSGS.